[1]Patent:WO2018/129227,2018,A1,.Locationinpatent:Paragraph00196;00197;00215;00216;00218
[2]Patent:WO2013/19548,2013,A1,.Locationinpatent:Page/Pagecolumn56-57
[3]DrugsoftheFuture,2014,vol.39,#10,p.685-692
[4]Patent:WO2017/118940,2017,A1,.Locationinpatent:Page/Pagecolumn61
[1]Patent:CN106831731,2017,A,.Locationinpatent:Paragraph0018;0019;0029;0030;0037;0038;0045;0046
[1]Patent:WO2013/19548,2013,A1,
[2]Patent:WO2013/19548,2013,A1,
[3]DrugsoftheFuture,2014,vol.39,#10,p.685-692
[4]Patent:WO2017/118940,2017,A1,
[5]Patent:WO2018/129227,2018,A1,
[1]Patent:WO2016/25904,2016,A1,.Locationinpatent:Paragraph00326
[1]Patent:WO2013/19548,2013,A1,
[2]Patent:WO2013/19548,2013,A1,
[3]DrugsoftheFuture,2014,vol.39,#10,p.685-692
[1]Patent:WO2013/19548,2013,A1
[2]Patent:WO2013/19548,2013,A1
[3]DrugsoftheFuture,2014,vol.39,p.685-692
[4]Patent:WO2017/118940,2017,A1
[5]Patent:WO2018/129227,2018,A1
[1]Patent:WO2013/19548,2013,A1
[1]Patent:WO2018/129227,2018,A1.Locationinpatent:Paragraph00196;00197;00215;00216;00218
[2]Patent:WO2013/19548,2013,A1.Locationinpatent:Page/Pagecolumn56-57
[3]DrugsoftheFuture,2014,vol.39,p.685-692
[4]Patent:WO2017/118940,2017,A1.Locationinpatent:Page/Pagecolumn61
[1]Patent:WO2013/19548,2013,A1
[2]Patent:WO2013/19548,2013,A1
[3]DrugsoftheFuture,2014,vol.39,p.685-692
[1]Patent:WO2013/19548,2013,A1
[2]Patent:WO2013/19548,2013,A1
[3]DrugsoftheFuture,2014,vol.39,p.685-692
Title: KPT-330, a potent and selective CRM1 inhibitor, exhibits anti-inflammation effects and protection against sepsis.
Journal: Biochemical and biophysical research communications 20180910
Title: KPT-330 inhibition of chromosome region maintenance 1 is cytotoxic and sensitizes chronic myeloid leukemia to Imatinib.
Journal: Cell death discovery 20180101
Title: Pharmacological treatment with inhibitors of nuclear export enhances the antitumor activity of docetaxel in human prostate cancer.
Journal: Oncotarget 20171219
Title: KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells.
Journal: Leukemia 20170101
Title: Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin.
Journal: Scientific reports 20170101
Title: SINE (selective inhibitor of nuclear export)--translational science in a new class of anti-cancer agents.
Journal: Journal of hematology & oncology 20140101
Title: Selective inhibitors of nuclear export (SINE)--a novel class of anti-cancer agents.
Journal: Journal of hematology & oncology 20140101
Title: Molecular cloning and cell cycle-dependent expression of mammalian CRM1, a protein involved in nuclear export of proteins.
Journal: The Journal of biological chemistry 19971121